Literature DB >> 23113703

Postnatal outcome in neonates with severe Rhesus c compared to rhesus D hemolytic disease.

Mirjam E A Rath1, Vivianne E H J Smits-Wintjens, Irene T M Lindenburg, Claudia C Folman, Anneke Brand, Inge L van Kamp, Dick Oepkes, Frans J Walther, Enrico Lopriore.   

Abstract

BACKGROUND: Neonates with Rhesus c (Rh c) hemolytic disease of the fetus and newborn (HDFN) are often managed in the same way as neonates with Rhesus D (Rh D) HDFN, although evidence to support this policy is limited. The objective of this study was to evaluate neonatal outcome in severe Rh c HDFN compared to Rh D HDFN. STUDY DESIGN AND METHODS: A retrospective study of (near-)term neonates with severe Rh c (n = 22) and Rh D HDFN (n = 103; without additional antibodies) admitted to the Leiden University Medical Center between January 2000 and October 2011 was conducted. The need for intrauterine transfusions (IUTs), phototherapy, exchange transfusions (ETs), and top-up transfusions up to 3 months of age were recorded and compared between both groups.
RESULTS: Although there was a trend for a slightly more severe antenatal course for Rh D HDFN reflected by an earlier need for and higher number of IUTs (median [interquartile range], 2 [1.5-4] vs. 2 [1-2] in Rh c HDFN; p = 0.070), no significant differences were found for the postnatal course between Rh c and Rh D group in days of phototherapy (mean, Days 4.8 and 4.6, respectively; p = 0.569), need for ET (50% vs. 44%, respectively; p = 0.589), and top-up transfusions (62% vs. 78%, respectively; p = 0.128).
CONCLUSION: Postnatal outcome in neonates with severe Rh c HDFN is similar compared to neonates with severe Rh D hemolytic disease in terms of days of phototherapy, need for ET, and need for top-up transfusions. These results justify a similar postnatal management of neonates with Rh D and Rh c HDFN.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23113703     DOI: 10.1111/j.1537-2995.2012.03937.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Neonatal outcomes of pregnancies affected by haemolytic disease of the foetus and newborn and managed with intrauterine transfusion: a service evaluation.

Authors:  Katherine A Birchenall; Sebastian E Illanes; Francisco Lopez; Timothy Overton; Rachel Liebling; Peter W Soothill; Sherif Abdel-Fattah; Mark Denbow
Journal:  Blood Transfus       Date:  2013-07-19       Impact factor: 3.443

2.  International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.

Authors:  Lani Lieberman; Enrico Lopriore; Jillian M Baker; Rachel S Bercovitz; Robert D Christensen; Gemma Crighton; Meghan Delaney; Ruchika Goel; Jeanne E Hendrickson; Amy Keir; Denise Landry; Ursula La Rocca; Brigitte Lemyre; Rolf F Maier; Eduardo Muniz-Diaz; Susan Nahirniak; Helen V New; Katerina Pavenski; Maria Cristina Pessoa Dos Santos; Glenn Ramsey; Nadine Shehata
Journal:  Br J Haematol       Date:  2022-04-12       Impact factor: 8.615

3.  Different Types of Minor Blood Group Incompatibility Causing Haemolytic Disease of Neonates in one of the National Children's Medical Centre in China.

Authors:  Mingchun Lin; Meixiu Liu; Shulian Zhang; Chao Chen; Jin Wang
Journal:  J Blood Med       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.